key: cord-0278332-3ravx9zl authors: May, Tom; Dawes, Jo; Fancourt, Daisy; Burton, Alexandra title: A qualitative study exploring the impact of the COVID-19 pandemic on People Who Inject Drugs (PWID) and drug service provision in the UK: PWID and service provider perspectives date: 2022-05-27 journal: nan DOI: 10.1016/j.drugpo.2022.103752 sha: 80467125fe256a05792c59638d21434d4f007c5d doc_id: 278332 cord_uid: 3ravx9zl Background : People Who Inject Drugs (PWID) are subject to distinct socio-structural inequalities that can expose them to high risks of COVID-19 transmission and related health and social complications. In response to COVID-19 mitigation strategies, these vulnerabilities are being experienced in the context of adapted drug treatment service provision, including reduced in-person support and increased regulatory flexibility in opioid substitution therapy (OST) guidelines. This study aimed to explore the longer-term impact of the pandemic on the health and wellbeing of PWID in the UK, including provider and client experiences of treatment changes. Methods : Interviews were conducted with 19 PWID and 17 drug treatment providers between May – September 2021, recruited from drug and homelessness charities providing treatment services and healthcare in the UK. Data were analysed using reflexive thematic analysis. Results : Most participants expressed ongoing fears of COVID-19 transmission, although socio-structural inequalities limited the contexts in which physical distancing could be practised. In addition, virus mitigation strategies altered the risk environment for PWID, resulting in ongoing physical (e.g. changing drug use patterns, including transitions to crack cocaine, benzodiazepine and pregabalin use) and socio-economic harms (e.g. limited opportunities for sex work engagement and income generation). Finally, whilst clients reported some favourable experiences from service adaptations prompted by COVID-19, including increased regulatory flexibility in OST guidelines, there was continued scepticism and caution among providers toward sustaining any treatment changes beyond the pandemic period. Conclusions : Whilst our findings emphasize the importance of accessible harm reduction measures attending to changing indices of drug-related harm during this period, there is a need for additional structural supports to ensure pre-existing disparities and harms impacting PWID are not exacerbated further by the conditions of the pandemic. In addition, any sustained policy and service delivery adaptations prompted by COVID-19 will require further attention if they are to be acceptable to both service users and providers. In response to the COVID-19 pandemic, governments worldwide implemented various mitigation measures -including physical distancing, mobility constraints and the closure of social, business and educational settings -in efforts to suppress the virus. Whilst these measures resulted in significant disruption to the lives of many (Brooks et al., 2020; Pierce et al., 2020) , their effects varied across populations and disproportionally impacted some of the most marginalised members of society (Bambra & Lynch, 2021; Bambra, Riordan, Ford, & Matthews, 2020) . This included People Who Inject Drugs (PWID), a population subject to pre-existing socio-structural inequalities (e.g. economic disadvantage, housing instability, stigma) that exposed them to high risks of COVID-19 transmission and related health and social complications (Bennett, Townsend, & Elliott, 2021; Kesten et al., 2021; Vasylyeva, Smyrnov, Strathdee, & Friedman, 2020) . Emerging research has documented the initial health and social impacts of the pandemic on PWID. Firstly, whilst mitigation measures were implemented in efforts to minimise contact and transmission, they disrupted daily routines and access to health and social care, and increased adverse mental health impacts, including isolation, boredom and anxiety (Bennett et al., 2021; Kesten et al., 2021; Roe et al., 2021) . Further, travel restrictions and border closures resulted in unstable drug markets and variable drug supplies, with some evidence of poly-drug use and substance substitution in response to temporary shortages at local levels (Croxford et al., 2021; Morin, Acharya, Eibl, & Marsh, 2021) . Finally, widespread business closures and a decline in opportunities for informal income-generating activities (e.g. begging, theft, sex work) exacerbated material and economic hardship for PWID, increasing vulnerability to both drug (e.g. opioid withdrawal) and health (e.g. hunger) related harms (Bennett et al., 2021) . A combination of these factors may be behind increased risk behaviours (e.g. syringe sharing, poly-drug use) (Nguyen & Buxton, 2021; Perri et al., 2021) and the acceleration of fatal and non-fatal opioid overdoses since the introduction of social distancing measures worldwide (Friedman & Akre, 2021; Glober et al., 2020; Rodda, West, & LeSaint, 2020; Slavova, Rock, Bush, Quesinberry, & Walsh, 2020) . In response to social distancing measures implemented during the earlier stages of the pandemic, many services reconfigured treatment and support for PWID to limit daily clinical encounters and reduce chances of virus transmission. For example, greater regulatory flexibility in opioid substitution therapy (OST) guidelines, including a shift from the daily supervised consumption of agonist medications (e.g. methadone and buprenorphine) to the provision of risk-assessed 'take-home doses', was introduced in the UK and US (Department of Health and Social Care, 2021; SAMHSA, 2020) 1 . Further measures -including the home delivery of harm reduction equipment (e.g. naloxone, injecting equipment), mobile outreach and expanded telephonic and telehealth services -were also established in attempts to increase treatment access in the context of reduced service availability (Aronowitz et al., 2021; Courser & Raffle, 2021; Mehtani et al., 2021; Nordeck, Buresh, Krawczyk, Fingerhood, & Agus, 2021) . Given how treatment engagement and retention is often compromised by inaccessibility andin the case of OST -the daily burden of supervised consumption (Frank, 2021; Frank et al., 2021; Hall, Le, Majmudar, & Mihalopoulos, 2021) , the pandemic presents a context in which these particular issues could be addressed and improved, at least temporarily. Although service providers reported concerns that adaptations may have decreased quality of care and led to increased instances of medication diversion and overdose (Hunter, Dopp, Ober, & Uscher-Pines, 2021) , emerging evidence from survey data generally conveys favourable outcomes among clients with limited occurrences of medication diversion or misuse (Figgatt, Salazar, Day, Vincent, & Dasgupta, 2021; Joseph, 1 Clinical guidance for commissioners and providers of drug and alcohol services regarding the safe delivery of OST during the pandemic, including possibilities of risk-assessed, relaxed pick-up and supervision requirements, was withdrawn on 19 th July 2021 (Department of Health & Social Care, 2021). Torres-Lockhart, Stein, Mund, & Nahvi, 2021) . Such contradictions reflect pre-existing debates on the use of telehealth modalities in healthcare (Scott Kruse et al., 2018) , as well as provider/client discussions regarding the optimal delivery of OST (Anthony et al., 2012; Frank, 2021) . Given how social and economic upheavals prompted by COVID-19 disproportionately impact the health and wellbeing of the most vulnerable (British Academy, 2021), the effects of the pandemic on PWID are likely to be long-lasting and are now only beginning to emerge. In this context, there remains a need for research with PWID and service providers beyond the initial stages of the pandemic, including any lasting and sustained impacts on drug-use patterns, drug-related harms and mental health previously identified (Bennett et al., 2021; Kesten et al., 2021) . Of further interest is how both providers and clients are continuing to respond to COVID-initiated service adaptions, including the continuation/discontinuation of remote working practices (e.g. telehealth, reduced in-person appointments) and the relaxation of OST regulations. Whilst studies have reported early insights from clients toward some of these changes (e.g. Kesten et al., 2021) , the perspectives and reactions of providers to altered treatment delivery are mainly absent, particularly in the UK. Understanding how service providers responded to the pandemic -including their comfort and willingness to use new forms of service delivery -can provide important practice and policy insights for whether seemingly temporary service responses to COVID-19 persist beyond this period. Therefore, the current study investigates the longer-term impacts of the pandemic on the health and wellbeing (including drug-related harms and risk behaviours) and everyday lives of PWID, as well as their experiences of treatment changes from the perspectives of both PWID and service providers. The research employed a qualitative design using semi-structured interviews with PWID and service providers from drug and homelessness charities providing treatment services and healthcare in England and Scotland. The study formed part of the UCL COVID-19 Social Study (UCL, 2021) , which explores the psychosocial effects of COVID-19 and associated restrictions on people living in the UK. Participants were interviewed about their experiences throughout the pandemic, including any implications for substance use, treatment engagement and delivery, and mental health and wellbeing. Ethical approval was provided by University College London research ethics committee [Project ID 6357/002]. The study was conducted between May -September 2021, a period when COVID-19 measures in England and Scotland were beginning to ease. COVID-19 measures were relaxed in England and most areas of Scotland on May 17 th 2021, allowing meetings of up to six people indoors and the majority of the indoor economy to reopen. The easing of these measures followed a national lockdown period between January and April 2021 that curbed social mixing outdoors and closed non-essential retail. The bulk of legal COVID-19 restrictions were lifted in England and most areas in Scotland on 19 th July 2021, although other types of restriction, notably self-isolation and international quarantine restrictions, remained. Appendix B provides a summary of the lockdown measures during the period of fieldwork. Convenience sampling was used to recruit both groups of participants, although as more interviews were conducted, we specifically advertised for under-represented characteristics within our sample to ensure diversity of gender, age, ethnicity and occupation in the case of service providers. In practice, this involved recruiting participants through several methods, including via social media and the UCL COVID-19 Social Study (including its newsletter and website). A national (with services across the UK) and two local drug and homelessness charities providing treatment services (located in Bristol and London) also advertised the research via bespoke posters and fliers within service settings and helped promote the research to eligible participants on our behalf. Clients were eligible to participate if they were (i) a current injecting opioid user or had been injecting opioids at some stage during the pandemic, (ii) aged over 18, and (iii) living in the UK. Service providers could participate if they (i) worked directly with PWID in drug services, (ii) were aged over 18, and (iii) living in the UK. Members of the research team provided eligible participants with details about the purpose of the research in writing and verbally and informed them that their involvement was voluntary. In addition, all participants signed a consent form, and demographic details (e.g. age, gender, ethnicity) were obtained. This information was received via email for participants who were interviewed remotely, or 'in person' if interviewed face-to-face. Interviews were conducted by TM (research fellow in social science), and JD (physiotherapist and research fellow in health inequalities) via telephone/video call (n=21) or in-person (n=15). All interviews were conducted individually apart from one interview, which was conducted with two PWID who requested to be interviewed together. Interviews followed a semi-structured topic guide for each participant group, which enabled data collection on the impact of the pandemic on substance use, treatment engagement and delivery and mental health and wellbeing (see appendix A for full topic guides). Interviews lasted an average of 38 minutes, were digitally recorded and transcribed verbatim by a professional transcription service. All interviews with service providers were conducted remotely (n=17) while the majority of client interviews were conducted face-to-face within either a drug service (n=9) or hostel facility where drug service clients resided (n=6). These interviews took place in a ventilated room and the researcher followed social distancing guidelines. The remaining client interviews were conducted remotely (n=4). Monetary compensation in the form of a £10 high street or supermarket voucher was offered to thank participants for their involvement. Data collection was conducted alongside data analysis and continued until theoretical saturation occurred across the entire sample (i.e. the point at which data emerged consistently or where no further data would develop new properties, categories or findings (Fusch & Ness, 2015) ). Transcripts were uploaded to NVivo version 12 software after de-identification. We used reflexive thematic analysis (Braun & Clarke, 2019 to analyse the data. This began with TM and JD independently reading and coding the same three transcripts. They then met to discuss and compare topics of potential significance to the research objectives. Following this process, TM then read and coded the remainder of the dataset, identifying further aspects of data that were then developed into a set of initial codes based on content grounded in the participant quotes. These codes were subsequently used to generate a set of key themes after being reviewed and analysed, which resulted in some codes being combined to form their own themes or sub-themes. To assist with this process, the research team met weekly as part of an ongoing iterative process to refine any new codes or themes produced. The use of two sources of qualitative data allowed for the triangulation and contextualisation of service user accounts with service provider interviews. We interviewed 36 participants (19 clients and 17 service providers). All client participants were recruited through drug and homelessness charities providing treatment services and healthcare ; three were recruited through a service based in London, 15 through a service in Bristol, and one through a national service. The average age of clients was 40 (range 24-59), with just over half identifying as female (n= 10). Most clients were White British (n=13) and at the time of interview most were temporarily housed, either in a hostel or with friends/family. All clients reported current or recent use of heroin or heroin and crack cocaine, and instances of alcohol, benzodiazepine and pregabalin use were also common. Table 1 provides an overview of client characteristics. Seventeen interviews were conducted with service providers from a single drug charity with treatment services located across England and Scotland. Service providers were from various occupational backgrounds within the drug and alcohol field, including clinical, management and frontline staff. The average age of service providers was 45 (range 28-67), with just over half identifying as male (n=9). The majority were White British (n=13). Table 2 provides an overview of service provider characteristics. Three primary themes were identified: (1) ongoing fears of COVID-19 infection but limited possibilities for guideline adherence; (2) increased social and drug-related harms, and; (3) experiences of service adaptations. Themes are shown in Figure 1 , along with their respective subthemes. (1) Ongoing fears of COVID-19 infection but limited possibilities for guideline adherence (2) Ongoing social and drug-related harms Increased barriers to and risks in generating income ( Greater flexibility in Opioid Substitution Therapy (OST) changes Remote service provision There was agreement among service providers that infections had been lower than expected among clients, which was both surprising and unexpected given earlier concerns: I guess that was something that was a relief in a way but also a bit of a surprise that they weren't as severely affected as we felt they might be…I Ongoing social and drug-related harms Clients and service providers reported how earlier lockdown measures had exacerbated several indices of drug-related harms, which were found to have ongoing and sustained impacts on drug use patterns and behaviours, and the ability to generate income. Both providers and clients agreed that lockdown measures had made it more difficult for clients to source heroin. Obstacles to conducting drug transactions in public spaces were described, as were reports of local drug supply shortages and increased adulteration. Although some clients responded to these constraints by ceasing or reducing their heroin use Clients In the initial phase of the pandemic, most services transitioned clients from the daily pick up of OST mediations to either weekly or fortnightly collection. In doing so, most providers reported unease and raised concerns about the loss of benefits linked to the 'structure' of supervised consumption, including peer support and regular monitoring, as well as the potential for misuse and diversion: Service providers reported how the use of remote services, including assessments and online psychosocial sessions, were also beneficial in terms of treatment engagement and outcomes. It was suggested that the increased accessibility that remote service provision provided reduced occurrences of missed appointments, which were previously met with punitive responses: As services weighed up whether to continue with forms of remote service provision, there was some suggestion that the quality of this treatment hinged on service provider comfort in delivering services via this method. Indeed, some providers described variability in responses among staff to providing remote provision: of those familiar and comfortable with responding to clients in this way (some people were tech savvy and very keen to do it and very proactive and set things up) and those less so (others had to be really pushed to do it because it was something new and something they weren't comfortable with, Services Manager, M, 41-45). Some service providers also described feeling inadequately equipped to deal with often challenging and complex issues experienced by clients over the phone, which, at times, led to feelings of powerlessness: People are more and more depressed, people are phoning up saying, "I'm going to kill myself", we're having to deal with that. We're not trained to deal with that. But people just phoning up in situations where I'm actually powerless to help them and, "Here's the number for the Samaritans and I'll refer you to be put on the waiting list for the service you need" (recovery coordinator, F, 51-55) Our findings are valuable, as to date, little is known about the ongoing impact of the pandemic on the health, wellbeing and daily lives of PWID. Furthermore, the experiences of service providers responding to the challenges faced by PWID are mainly absent, particularly in the UK whereto our knowledgequalitative research has focused exclusively on the perspectives of clients (Kesten et al., 2021) . Therefore, this study provides new insights into the social and psychological impact of the COVID-19 pandemic on PWID and their experiences of service adaptations in this context. Our findings suggest PWID remain fearful of COVID-19, yet broader socio-structural inequalities, including accommodation conditions and economic hardship, are limiting the ability to comply with public health measures. This confirms earlier quantitative findings that socioeconomically vulnerable populations and PWID have fewer possibilities to adhere to guidelines (Beale et al., 2021; Genberg et al., 2021) . Our data adds qualitative insights into what these limited possibilities may be and how they are continuing to affect this population. For instance, the risk of financial and material hardship and the daily burden of keeping well compelled some to disregard social distancing despite risks of COVID-19 transmission, as evidenced by a continued engagement in street-based sex work among some clients. As reported elsewhere (e.g. Kesten et al., 2021) , accommodation settings and living arrangements were also unconducive to social distancing, which we also found elevated distress by limiting the contexts in which physical distancing could be practised. Feelings of vulnerability to infection have led to poorer mental health among other population groups: those with long-term health conditions, for example, reported fear and anxiety related to the consequences of COVID-19 infection (Fisher, Roberts, McKinlay, Fancourt, & Burton, 2021) . Our findings suggest a similar, ongoing occurrence among PWID. Any additional burden on mental health among this population is particularly concerning given PWID already experience a high prevalence of mental health symptoms and barriers to accessing mental health services (Genberg et al., 2019; Priester et al., 2016) as well as it being a risk factor for ongoing substance use (Pilowsky, Wu, Burchett, Blazer, & Ling, 2011) . Hence, whilst these findings highlight the importance of accessible mental health support in pandemic response measures -including access to low-threshold, co-located psychological services -there is a need for additional support attending to the socialstructural vulnerabilities that shape COVID-19 related harms, including appropriate housing, shelter, food and economic support. Our findings provide further evidence of how COVID-19 has altered a number of indices of drug-related harm among PWID, including physical (e.g. changes in drug use patterns and characteristics) and socio-economic (e.g. riskier sex work engagement and income generation) harms. Volatility in the global heroin supply and reduced availability and quality of substances at local level have been observed during the pandemic (Bennett et al., 2021) . Difficulties in sourcing drugs is particularly problematic as there is evidence that PWID may substitute or transition to more readily available but unfamiliar substances in attempts to abate withdrawal symptoms (Day et al., 2003; Harris, Forseth, & Rhodes, 2015; May, Holloway, Buhociu, & Hills, 2020) . Our findings, along with earlier data from the pandemic (Croxford et al., 2021; Kesten et al., 2021; Morin et al., 2021) , suggest that similar patterns may have occurred due to accessibility issues. However, our data adds further insight in that some changes to drug use appeared to be temporary, with clients reverting to the sole use of heroin as availability returned. In contrast, there was some evidence to suggest the development of increased tolerance and dependence on substances initiated in response to shortages during the earlier stages of the pandemic, including crack cocaine, benzodiazepines and pregabalin. Although we did not identify any occurrences of significant harm, the observed shifts to increased depressant polydrug use is a concern given the potential for harm (including increased vulnerability to overdose, BBV infection (Harris et al., 2015; Horyniak et al., 2015) ), particularly if used alongside opioids (Macleod et al., 2019; McAuley, Matheson, & Robertson, 2022) . Switches to crack cocaine use during this period are also problematic given users' proclivity to share pipes, increasing COVID-19 transmission risks (Harris, 2020) . In this context, increased take-home naloxone distribution, removing barriers to treatment, public health messaging, and access to blood-borne virus testing are essential to minimize various drug-related harms associated with limited availability, including withdrawal. The changes to crack-cocaine reported by participants in our study and the increasing availability and prevalence of its use during the pandemic more broadly (EMCDDA., 2021) also necessitate harm reduction measures to help reduce COVID-19 infection and respiratory-based health harms among this population of users (Harris, 2020) . Opportunities for informal and illegal income generation were also reportedly reduced by the pandemic and found to impact the wellbeing of PWID. Interview narratives suggested those most impacted were women reliant on survival sex work due to their increased economic precarity during this period and limited access to social protection (Platt et al., 2020) . There is an extensive body of research drawing attention to how economic vulnerability renders this population more susceptible to health-related harms, particularly if drug use is part of this dynamic (Ogden et al., 2021) . This includes reduced possibilities to negotiate prices and screen clients, which may contribute to unprotected sex and gender-based violence, both of which are risk factors for HIV (Strathdee et al., 2015) . Our findings suggest the pandemic has compounded many of these issues and heightened the possibility of these harms occurring in this context. For instance, a reduced demand for streetbased sex work and increased competition from online sexual services in the immediate period following the relaxation of social distancing measures severely limited some sex-workers agency over transactions, including capacity for safer sex practices, client screening and price negotiation. These hazards played out alongside other risks, with some women obliged to enter into relationships with male partners for economic support. These women were especially vulnerable to exploitation given how gender inequitable power relations often play out in drug-using partnerships, notably through the control of resources generated through sex work (Bourgois, Prince, & Moss, 2004) . Hence, there is an urgent need for financial support and protection for those with no option but to continue sex working during this period (Platt et al., 2020) . COVID-19 has created a context in which innovative service responses and regulatory changes can be implemented and examined, thereby providing preliminary insight into the feasibility of future service adaptations. A shift to weekly or fortnightly OST pickups during the earlier stages of the pandemic were well received and afforded a number of benefits to clients, including stigma reduction, increased day-to-day freedom, and greater control over daily dosage, as reported elsewhere (Krawczyk, Fawole, Yang, & Tofighi, 2021; Nordeck et al., 2021) . Building on these earlier findings, our data provides insights into how clients and providers perceived changes back to daily supervised consumption following a relaxation in social distancing rules. Most clients expressed displeasure at this reversal given the aforementioned benefits and a perception that they had 'proved' themselves capable of managing take-home doses. This is largely in contrast to a continued scepticism and caution among providers toward any sustained relaxation of regulations, as similarly reported elsewhere (Hunter et al., 2021; Krawczyk et al., 2021) . Whilst these contradictions reflect long-standing debate between client/provider preferences regarding the optimal delivery of OST (Frank, 2021) , services may wish to take stock of the benefits afforded from these changes during this period (e.g. Figgatt et al., 2021; Frank et al., 2021; Kesten et al., 2021) . This is especially important given the daily burden of supervised consumption was often cited as one reason behind low retention rates in OST prior to the pandemic (Frank, 2021; Nolan et al., 2015) . Further research is required to enable best practice in balancing the potential risks and benefits of relaxed regulations, including objective patient outcome data to determine whether flexibilities have improved or worsened treatment outcomes, medication diversion and overdose. Whilst remote service provision, including the use of telephonic methods, were implemented rapidly to increase service access, most services reported retaining some elements of remote operating at the time of data collection and envisioned their continued use in the future. Although providers and some clients reported benefits of virtual forms of treatment, including increased access and the ability to reach clients unwilling to engage with face-toface psychosocial services, our findings also highlighted several disruptions to care due to the ongoing use of such methods. These were mostly related to difficulties assessing client health and wellbeing virtually and perceived reductions in levels of support provided. This is in line with earlier research reporting a lack of provider comfort and willingness in using such methods (Aronowitz et al., 2021; Goldsamt, Rosenblum, Appel, Paris, & Nazia, 2021) , and disrupted support routines among clients (Kesten et al., 2021) . PWID also face disparities in accessing telehealth services, and although innovationsincluding onsite, private rooms with sanitized telephones (Quiñones et al., 2021) and the distribution of donated mobile phones (Komaromy et al., 2021) have proved successful in offsetting some of these issues, there remains a need to ensure access to telehealth services is more evenly distributed among PWID. Similarly, providers must be equipped and comfortable with using telehealth methods as their use becomes increasingly integrated in treatment frameworks and routine health care (Aronowitz et al., 2021) . The development of an improved telehealth infrastructure, including dedicated and tailored telehealth training curricula for health and social care workers, has been recommended (Fisk, Livingstone, & Pit, 2020; Thomas et al., 2020) , and may have similar utility for those working in drug services. Our findings also suggest the need for further research into the effectiveness of remote service provision on client engagement and treatment outcomes. This study is not without limitations. First, the sampling strategy may be biased toward those participants willing or able to participate. It is possible the views expressed in this study differ from those unwilling or unable to participate and may contribute to the under-reporting of certain experiences (e.g. overdose). Second, client and provider interviews were conducted over several months and may therefore reflect the impact of time-specific events or experiences, including lockdown measures or service alterations. For example, interviews were conducted at a time when COVID-19 legal restrictions were lifted in UK, including the removal of social distancing and social contact limits and the reopening of businesses (Institute for Government Analysis, 2021; The Scottish Parliament, 2022). The timing of interviews therefore require consideration when interpreting the findings. Nevertheless, participants were able to recount both current and retrospective experiences during periods when more restrictive social distancing measures were in place (e.g. stay at home orders). Third, whilst the study includes the experiences of providers and clients from various regions of England and Scotland, regional differences in service provision, drug markets and lockdown measures may mean perspectives and experiences vary in ways that are not fully captured in this research. Finally, despite efforts to recruit a geographically diverse sample, the majority of service users were recruited from a single service. This is perhaps reflective of the challenges recruiting participants for qualitative studies during the pandemic, particularly from organisations or services that have been under significant pressure to adapt and manage services since its onset. In attempts to make data collection as non-burdensome and straightforward for organisations as possible, a convenience sampling method was therefore adopted, resulting in the collection of data from participants most accessible at the time of the study. However, as there were also difficulties conducting remote interviews with the study population during this period (e.g. limited phone ownership, housing instability, see also Parkin et al. (2021) ), it was necessary for the research team to find ways to facilitate the full participation of this population. This entailed conducting some face-to-face interviews at services accessible (geographically and logistically) to the research team. While the geographic makeup of service users in this study is therefore somewhat distorted, it does include the insights and experiences of those who would not have been able to participate in the study if it were conducted entirely via remote methods. The inclusion of service providers in our study meant we could also involve geographically diverse perspectives, given that no recruitment issues were experienced with this group. Despite these limitations, the paper is the first known study in the UK to interview both drug service providers and PWID about their ongoing experiences of the COVID-19 pandemic. Understanding the experiences of the latter is particularly important given their increased marginalisation and vulnerability during this period. Thus, the study provides a voice to a seldom heard group through in-depth, semi-structured interviews, which can provide important insights for future policy directions and service provision. This paper provides new insights into the ongoing impact of the pandemic on the mental health, drug-related harms and behaviours of PWID as well as adaptations to treatments and services. Whilst our findings emphasize the importance of accessible support measures attending to the immediate priorities of PWID during this period (including access to lowthreshold, co-located psychological services, naloxone, NSP provision, low-threshold OST programmes) there is a need for additional support addressing the social-structural vulnerabilities that disproportionality affect PWID. This includes the provision of appropriate housing, shelter, food and economic support to ensure pre-existing disparities and harms are not exacerbated further by the conditions of the pandemic. Drug service adaptations initiated in response to the pandemic also require further attention to ensure future treatment is acceptable and ultimately responsive to the needs of PWID. In this context, it is important that any innovations in treatment are informed by the knowledge and expertise of PWID themselves, given the benefits afforded by some service adaptations (e.g. relaxation of OST). However, service deliverers may require further support (e.g. tailored training curricula) to increase acceptance of any sustained policy and service delivery adaptations prompted by COVID-19. The datasets presented in this article are not readily available because they contain information that could compromise the privacy of research participants. Requests to access the datasets should be directed to d.fancourt@ucl.ac.uk. AB and DF contributed to the conception and design of the study. TM was responsible for data collection and wrote the first draft of the manuscript. TM and JD performed the formal data analysis. AB, DF, and JD assisted with review and editing. All authors contributed to manuscript revision, read, and approved the submitted version. Methadone prescribing under supervised consumption on premises: A Scottish clinician's perspective on prescribing practice Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives The Unequal Pandemic: COVID-19 and Health Inequalities The COVID-19 pandemic and health inequalities Deprivation and exposure to public activities during the COVID-19 pandemic in England and Wales The COVID-19 Pandemic and the Health of People Who Use Illicit Opioids in New York City, the First 12 Months The Everyday Violence of Hepatitis C Among Young Women Who Inject Drugs in San Francisco Reflecting on reflexive thematic analysis Can I use TA? Should I use TA? Should I not use TA? Comparing reflexive thematic analysis and other pattern-based qualitative analytic approaches. Counselling and Psychotherapy Research The Covid Decade: Understanding the long-term societal impacts of COVID-19 London: The British Academy Brooks With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services providers-of-services-for-people-who-use-drugs-or-alcohol/covid-19-guidance-forcommissioners-and-providers-of-services-for-people-who-use-drugs-or-alcohol EMCDDA The impact of the COVID-19 pandemic on mental health and well-being of people living with a long-term physical health condition: a qualitative study Telehealth in the Context of COVID-19: Changing Perspectives in Australia, the United Kingdom, and the United States A chance to do it better: Methadone maintenance treatment in the age of Covid-19 It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives COVID-19 and the Drug Overdose Crisis: Uncovering the Deadliest Months in the United States Are we there yet? Data saturation in qualitative research The health and social consequences during the initial period of the COVID-19 pandemic among current and former people who inject drugs: A rapid phone survey in Engagement in treatment for depression among people who inject drugs in Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis The impact of COVID-19 on opioid treatment programs in the United States. Drug and Alcohol Dependence Barriers to accessing opioid substitution treatment for opioid use disorder: A systematic review from the client perspective. Drug and Alcohol Dependence An urgent impetus for action: safe inhalation interventions to reduce COVID-19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom It's Russian roulette": adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage How do drug market changes affect characteristics of injecting initiation and subsequent patterns of drug use? Findings from a cohort of regular heroin and methamphetamine injectors in Melbourne, Australia Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study Timeline of UK government coronavirus lockdowns and measures Reimagining patientcentered care in opioid treatment programs: Lessons from the Bronx during COVID-19 Living Under Coronavirus and Injecting Drugs in Bristol (LUCID-B): A qualitative study of experiences of COVID-19 among people who inject drugs Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records Not what the doctor ordered: Motivations for nonmedical prescription drug use among people who use illegal drugs From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario Pathways between COVID-19 public health responses and increasing overdose risks: A rapid review and conceptual framework The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting Adapting a Lowthreshold Buprenorphine Program for Vulnerable Populations During the COVID-19 A typology of sex work and health behaviours among people who inject drugs Conducting rapid qualitative research amongst people with experience of rough sleeping in London during the COVID-19 pandemic A qualitative study on overdose response in the era of COVID-19 and beyond: how to spot someone so they never have to use alone Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population Depressive Symptoms, Substance Use, and HIV-Related High-Risk Behaviors Among Opioid-Dependent Individuals: Results From the Clinical Trials Network Sex workers must not be forgotten in the COVID-19 response Treatment Access Barriers and Disparities Among Individuals with Co-Occurring Mental Health and Substance Use Disorders: An Integrative Literature Review Treating Opioid Use Disorder in Puerto Rico During the COVID-19 Pandemic: Providers' Leadership Efforts in Unprecedented Times Opioid Overdose-Related Emergency Department Visits and Accidental Deaths during the COVID-19 Pandemic Isolation, Solitude and Social Distancing for People Who Use Drugs: An Ethnographic Perspective Opioid Treatment Program (OTP) Guidance Evaluating barriers to adopting telemedicine worldwide: A systematic review Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug and Alcohol Dependence Substance Use and HIV Among Female Sex Workers and Female Prisoners: Risk Environments and Implications for Prevention, Treatment, and Policies Timeline of Coronavirus (COVID-19) in Scotland Building on the momentum: Sustaining telehealth beyond COVID-19 Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks The authors would like to thank Bristol Drugs Project, Change Grow Live, Pathway and Outside Edge for their assistance with recruitment of participants for this study, as well as those people who gave up their time to take part and contribute to the study. The authors would also like to thank Dr Alison McKinlay and Dr Katey Warran for their assistance during the recruitment and analysis stages of this paper. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.